Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Luye Pharma Group ( (HK:2186) ) is now available.
Luye Pharma Group Ltd. held its Annual General Meeting on May 28, 2025, where all proposed resolutions were passed. Key resolutions included the re-election of board members, the re-appointment of Ernst & Young as auditors, and granting mandates for share issuance and repurchase. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued strategic growth and operational efficiency.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.13 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company incorporated in Bermuda, focusing on the development, production, and sale of innovative medications. The company operates in the healthcare industry, providing a range of pharmaceutical products to meet diverse medical needs.
Average Trading Volume: 43,565,274
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.43B
Learn more about 2186 stock on TipRanks’ Stock Analysis page.